TrialJournal of neuro-oncology2017
Phase II study of tivozanib, an oral VEGFR inhibitor, in patients with recurrent glioblastoma.
Jayashree Kalpathy-Cramer et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
52 papers cite it
this paperpooled itcites it